Good clinical practice (GCP). 25%
Informed consent in human trials. 10%
Ethical clinical study design and conduct. 25%
Regulatory guidance documents. 10%
Pre-Market Application (PMA) and New Drug Applications (NDA) submissions. 20%
International clinical trials. 10%